Monopar Therapeutics Cash Flow Statement

Cash Flow Statement Dec2016 Dec2017 Dec2018 Dec2019 Dec2020 Dec2021 Dec2022 Dec2023 Dec2024
Operating Activities
Net Income -1.19M-16.55M-3.30M-4.32M
Share-based Compensation 0.31M0.53M1.01M1.32M1.64M1.90M4.55M
Gains from Investment Securities 13.50M-0.07M0.06M-0.01M0.08M0.05M0.10M
Cash from Operations -1.19M-2.63M-2.68M-3.02M-4.66M-7.32M-7.23M-7.86M-6.40M
Change in Working Capital
Change in Accured Expenses -0.01M0.25M0.09M0.24M0.45M0.40M1.48M-1.33M0.51M
Other Working Capital Changes -0.00M0.13M0.00M-0.01M0.00M-0.09M-0.17M0.02M0.02M
Investing Activities
Acquisitions 4.83M
Change in Acquisitions & Divestments 12.81M0.99M
Cash from Investing Activities -4.92M4.93M-14.34M
Financing Activities
Other financing activities 0.97M
Cash from Financing Activities 1.26M9.54M-0.21M9.35M8.18M10.88M0.03M2.03M59.29M
Additional items
Exchange Rate Effect -0.00M-0.01M0.00M0.00M-0.00M-0.02M0.00M
Change in Cash 0.07M6.91M-2.89M6.32M3.52M3.57M-12.12M-0.92M38.55M
Free Cash Flow -1.19M-2.63M-2.68M-3.02M-4.66M-7.32M-7.23M-7.86M-6.40M
Net Cash Flow 0.07M6.91M-2.89M6.33M3.52M3.56M-12.11M-0.90M38.55M